Scarica l'app Stockscreener
112.50
2.45%
-2.83
Dopo l'orario di chiusura:
112.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVTY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$115.33
Aprire:
$114.83
Volume 24 ore:
1.60M
Relative Volume:
1.12
Capitalizzazione di mercato:
$12.75B
Reddito:
$2.77B
Utile/perdita netta:
$286.61M
Rapporto P/E:
47.87
EPS:
2.35
Flusso di cassa netto:
$524.11M
1 W Prestazione:
+7.73%
1M Prestazione:
+16.86%
6M Prestazione:
+18.55%
1 anno Prestazione:
-5.88%
Intervallo 1D:
$111.86
$115.44
Intervallo di 1 settimana:
$102.71
$115.78
Portata 52W:
$81.36
$128.28
Revvity Inc Stock (RVTY) Company Profile
Nome
Revvity Inc
Settore
Industria
Telefono
781-663-6900
Indirizzo
77 4TH AVENUE, WALTHAM
Confronta RVTY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
112.50 | 13.08B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-12-09 | Iniziato | Goldman | Neutral |
| 2025-10-16 | Iniziato | Guggenheim | Neutral |
| 2025-05-01 | Aggiornamento | UBS | Neutral → Buy |
| 2025-01-10 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-07-08 | Iniziato | Leerink Partners | Outperform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-23 | Ripresa | Goldman | Buy |
Mostra tutto
Revvity Inc Borsa (RVTY) Ultime notizie
Surprises Report: Can Revvity Inc outperform in the next rallyJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
How is Revvity's stock performance compared to other health care stocks? - MSN
Revvity Stock Gains On Solid Early Q4 Results, Upbeat Outlook - Sahm
The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance - Yahoo Finance
What's Going On With Revvity Stock Wednesday?Revvity (NYSE:RVTY) - Benzinga
Weekly Trades: Is Revvity Inc showing insider buyingPortfolio Update Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Revvity stock surges on exceeding profit forecasts - MSN
How (RVTY) Movements Inform Risk Allocation Models - Stock Traders Daily
Revvity (NYSE:RVTY) Shares Gap UpHere's Why - MarketBeat
Revvity expects to report Q4 revenue of $772 million - MSN
Revvity Inc expects existing end market trends to continue into 2026presentation - marketscreener.com
Risk Hedge: What dividend safety score for Revvity Inc stock2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Revvity Raises 2025 Outlook With Strong Preliminary Results - TipRanks
Revvity Inc Expect Existing End Market Trends To Continue Into 2026Presentation - TradingView — Track All Markets
Stock Market Today: Nasdaq 100, S&P 500, Dow Jones Futures Lag Ahead Of December CPI Print— JPMorgan, Alphabet, Five9 In Focus (UPDATED) - Benzinga
S&P 500 Futures Decline in Premarket Trading; L3Harris Technologies, Revvity Lead - Barron's
Revvity (NYSE:RVTY) Issues FY 2025 Earnings Guidance - MarketBeat
Revvity Stock Pre-Market (+4.9%): Exceeds Top-End of EPS and Revenue Guidance - Trefis
Why Is RVTY Stock Surging in Premarket? Q4 Revenue Outlook Tops Expectations - Tokenist
Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads. - Barron's
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance - PharmiWeb.com
Revvity says it will exceed 2025 profit forecast range - MSN
Revvity sale, perché la società prevede di superare le previsioni di profitto per il 2025 - TradingView — Track All Markets
Revvity rises as co expects to exceed 2025 profit forecast - TradingView — Track All Markets
Revvity Preliminary Q4 Revenue Tops Estimates; Shares Rise After Hours - marketscreener.com
RVTY Stock Shows Positive Outlook with Analyst Consensus - GuruFocus
Revvity (RVTY) Sees Stock Uptick After Q4 Revenue Announcement - GuruFocus
RVTY Projects Revenue Growth for Q4 and 2025 - GuruFocus
Revvity expects to exceed Q4 guidance with 6% revenue growth - Investing.com
Revvity expects to exceed Q4 guidance with 6% revenue growth By Investing.com - Investing.com India
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models - TradingView — Track All Markets
Revvity collaborates with Eli Lilly to expand access to AI drug discovery models - BioSpectrum Asia
Why Revvity (RVTY) Is Up 6.4% After New Lilly AI Drug Discovery Partnership Integration - simplywall.st
Revvity's (NYSE:RVTY) Earnings Trajectory Could Turn Positive as the Stock Climbs 6.4% This Past Week - 富途牛牛
Revvity and Lilly partner to accelerate AI drug discovery models - Indian Pharma Post
About Us | Laser Focus WorldRevvity, Inc. Common Stock (NYSE:RVTY) Price Chart - FinancialContent
Key facts: Eli Lilly to acquire Ventyx for $1.2B; Mounjaro pricing in India; AI partnership with Revvity - TradingView — Track All Markets
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models - PharmiWeb.com
Revvity, Inc. Collaborates with Eli Lilly and Company to Expand Access to Ai Drug Discovery Models - marketscreener.com
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery - Seeking Alpha
Revvity collaborates with Lilly to expand access to AI drug discovery models - marketscreener.com
Revvity announces collaboration with Eli Lilly on AI drug discovery models - TipRanks
Revvity, Lilly Partner To Expand Access To AI Drug Discovery Models - Nasdaq
Revvity (NYSE:RVTY) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 5.1% this past week - simplywall.st
Will Revvity Inc. (PKN) stock outperform global peersJuly 2025 Action & High Conviction Investment Ideas - ulpravda.ru
Can Revvity Inc. (PKN) stock ride next bull market cycle2025 Volume Leaders & High Conviction Trade Alerts - ulpravda.ru
Is Revvity Inc. stock a good choice for value investorsJuly 2025 Short Interest & High Yield Equity Trading Tips - ulpravda.ru
Revvity Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Is Revvity Inc. (PKN) stock a buy on weakness2025 Retail Activity & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Will Revvity Inc. stock reach all time highs in 2025Market Risk Report & Weekly Watchlist for Hot Stocks - ulpravda.ru
Revvity Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Revvity Inc Azioni (RVTY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.51%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):